Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon 442-721, Korea.
J Neuroinflammation. 2012 Feb 18;9:34. doi: 10.1186/1742-2094-9-34.
The peroxisome proliferator-activated receptor (PPAR)-α activator, 5,8,11,14-eicosatetraynoic acid (ETYA), is an arachidonic acid analog. It is reported to inhibit up-regulation of pro-inflammatory genes; however, its underlying mechanism of action is largely unknown. In the present study, we focused on the inhibitory action of ETYA on the expression of the chemokine, CCL2/MCP-1, which plays a key role in the initiation and progression of inflammation.
To determine the effect of ETYA, primary cultured rat astrocytes and microglia were stimulated with IFN-γ in the presence of ETYA and then, expression of CCL2/MCP-1 and MAPK phosphatase (MKP-1) were determined using RT-PCR and ELISA. MKP-1 mRNA stability was evaluated by treating actinomycin D. The effect of MKP-1 and human antigen R (HuR) was analyzed by using specific siRNA transfection system. The localization of HuR was analyzed by immunocytochemistry and subcellular fractionation experiment.
We found that ETYA suppressed CCL2/MCP-1 transcription and secretion of CCL2/MCP-1 protein through up-regulation of MKP-1mRNA levels, resulting in suppression of c-Jun N-terminal kinase (JNK) phosphorylation and activator protein 1 (AP1) activity in IFN-γ-stimulated brain glial cells. Moreover, these effects of ETYA were independent of PPAR-α. Experiments using actinomycin D revealed that the ETYA-induced increase in MKP-1 mRNA levels reflected an increase in transcript stability. Knockdown experiments using small interfering RNA demonstrated that this increase in MKP-1 mRNA stability depended on HuR, an RNA-binding protein known to promote enhanced mRNA stability. Furthermore, ETYA-induced, HuR-mediated mRNA stabilization resulted from HuR-MKP-1 nucleocytoplasmic translocation, which served to protect MKP-1 mRNA from the mRNA degradation machinery.
ETYA induces MKP-1 through HuR at the post-transcriptional level in a receptor-independent manner. The mechanism revealed here suggests eicosanoids as potential therapeutic modulators of inflammation that act through a novel target.
过氧化物酶体增殖物激活受体(PPAR)-α激活剂,5,8,11,14-二十碳四烯酸(ETYA)是一种花生四烯酸类似物。据报道,它可抑制促炎基因的上调;然而,其作用机制在很大程度上尚不清楚。在本研究中,我们专注于 ETYA 对趋化因子 CCL2/MCP-1 表达的抑制作用,CCL2/MCP-1 在炎症的启动和进展中起着关键作用。
为了确定 ETYA 的作用,用 IFN-γ 刺激原代培养的大鼠星形胶质细胞和小胶质细胞,然后用 RT-PCR 和 ELISA 测定 CCL2/MCP-1 和丝裂原活化蛋白激酶磷酸酶(MKP-1)的表达。通过用放线菌素 D 处理评估 MKP-1 mRNA 的稳定性。使用特异性 siRNA 转染系统分析 MKP-1 和人抗原 R(HuR)的作用。通过免疫细胞化学和亚细胞分级实验分析 HuR 的定位。
我们发现 ETYA 通过上调 MKP-1mRNA 水平抑制 CCL2/MCP-1 的转录和 CCL2/MCP-1 蛋白的分泌,从而抑制 IFN-γ 刺激的脑胶质细胞中 JNK 磷酸化和 AP1 活性。此外,ETYA 的这些作用不依赖于 PPAR-α。用放线菌素 D 进行的实验表明,ETYA 诱导的 MKP-1 mRNA 水平增加反映了转录物稳定性的增加。使用小干扰 RNA 的敲低实验表明,这种 MKP-1 mRNA 稳定性的增加依赖于 HuR,HuR 是一种已知可促进增强的 mRNA 稳定性的 RNA 结合蛋白。此外,ETYA 诱导的 HuR 介导的 mRNA 稳定化导致 HuR-MKP-1 核质易位,从而保护 MKP-1 mRNA 免受 mRNA 降解机制的影响。
ETYA 通过 HuR 在受体非依赖性方式在转录后水平诱导 MKP-1。这里揭示的机制表明,类二十烷酸作为通过新型靶标发挥作用的炎症潜在治疗调节剂。